Topic starter
There is a new scientific article which looks at which psychedelic treatments are currently the best researched for PTSD, and the risks and limitations involved.
In it, we discuss:
The authors conducted a systematic review to see which psychedelics have the most data for the treatment of post-traumatic stress disorder. In doing so, they looked not only at efficacy, but also at safety and at characteristics of the patient populations studied.
The real focus of this article is not on classical psychedelics such as psilocybin or LSD, but mainly on MDMA-assisted psychotherapy and intravenous ketamine. Of the 13 included studies, six dealt with MDMA and seven with ketamine. The outcomes were mixed, but MDMA showed statistically significant improvement in PTSD symptoms in four of the six studies. For intravenous ketamine, the same was true for three of the seven studies.
This review also shows that both treatments were generally reasonably well tolerated when given under medical or therapeutic supervision. A large proportion of the studies were conducted in mainly civilian populations, while only a smaller proportion specifically targeted veterans.
Importantly, however, the authors emphatically warn about limitations of this field of research. For instance, expectancy effects can be large, good blinding is difficult because people often notice which drug they have been given, and studies are still relatively limited in number and design. In addition, the authors conclude that randomised studies are currently lacking for psilocybin and LSD in PTSD.
In one sentence, this article concludes that MDMA and intravenous ketamine currently have the most scientific support in PTSD, but that the evidence base still has limitations and that classic psychedelics such as psilocybin and LSD still need much more research.
Spoiler
New article description
Abstract
Purpose: The purpose of this review is to evaluate which psychedelics have the most efficacy data to support their use in the treatment of posttraumatic stress disorder (PTSD). This review also aims to assess safety data and concerns related to psychedelic therapies and identify demographic characteristics that may influence clinical outcomes.
Summary: A systematic review of the literature was conducted on PubMed, Web of Science, and Scopus to identify randomised controlled studies evaluating the use of psychedelic therapy in treatment of PTSD. Thirteen studies met our inclusion criteria and were included in the review. Six studies evaluated 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy, while 7 studies evaluated ketamine. Study findings regarding efficacy were mixed. Four of the 6 studies evaluating MDMA-assisted psychotherapy demonstrated statistically significant improvement in PTSD symptoms, while 3 of the 7 studies evaluating intravenous ketamine (ketamine IV) demonstrated statistically significant efficacy (eg, reduced PTSD symptoms, durable effect) in relation to comparators. Both therapies were generally well tolerated. The majority of studies were conducted in primarily civilian populations, with one MDMA study and 2 ketamine IV studies focused on veterans.
Conclusion: MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under supervision may lead to improvements in PTSD symptoms, with the medications being generally well tolerated. However, caution should be used when interpreting study results due to limitations such as treatment expectancy effect and the potential for inadequate blinding. Randomised controlled studies of other psychedelics (eg, psilocybin, lysergic acid diethylamide) are needed to assess their utility in PTSD.
Keywords: PTSD; MDMA; ketamine; psychedelics; psychotherapy; systematic review; psilocybin; LSD.
Posted : 18 March 2026 14:26